Double-blinded randomized control study investigating intrathecal morphine as an additive to spinal anesthesia in patients undergoing elective total knee arthroplasty. The investigators aim to include a total of 120 patients, randomized to two equal groups. Participants in the intervention group are administered intrathecal 0,2mg morphine and 12,5mg bupivacaine for spinal anaesthesia. Participants in the placebo group are administered 12.5mg bupivacaine and saline to match the volume of intervention goup. Primary end points are opioid consumption and possible adverse effects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
120
Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
South Carelia Central Hospital
Lappeenranta, Finland
RECRUITINGintravenous oxycodone consumption
Cumulative postoperative consumption
Time frame: 48 hours
Adverse effects of 0,2mg intrathecal morphine
Possible nausea, vomiting, itching and respiratory depression
Time frame: 48 hours
Mobilization time
Assessing the time to ambulation
Time frame: 48 hours
Patient satisfaction
Telephone interview 28 days after surgery
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.